-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 19, Rongchang Biologics Claudin 18.
According to the PharmaGo database, Rongchang Bio-HER2 ADC Vidicuzumab has been approved for marketing, and c-Met ADC RC108 and MSLN (mesothelin) ADC RC88 are in phase I clinical phase
In June 2021, Rongchang Biologics registered the first human clinical trial of RC118 on the American Clinical Network for the treatment of solid tumors
At present, there are 3 domestic manufacturers that declare Claudin 18.
The target ADC drug SYSA1801 of CSPC has been clinically approved in the United States and China, and it is planned to be developed for the treatment of advanced pancreatic cancer with positive expression of Claudin 18.
Claudin 18 (CLDN18) is a protein encoded by the CLDN 18 gene, belonging to the Tight Junction Protein family (Tight JunctionProteins), which can control the molecular flow between layers of cells
CLDN 18.